MEDPLUS · NSE
Medplus Health Services Limited
₹659.65
+0.86% (+₹5.65)
Prev. close
₹654
Volume
87,557
Delivery %
59.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Medplus Health Services Limited
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness items, such as prescription medicines, over-the-counter drugs, vitamins, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Dr. Gangadi Madhukar Reddy
Headquarters
Hyderabad
Employees
28,872
Website
medplusindia.comExchange
View on NSE ↗Key stats
Market cap
₹7,921.58 Cr
P/E ratio (TTM)
37.6
EPS (TTM)
₹17.53
Beta (1Y · daily vs NIFTY 50)
0.54
Beta (5Y · monthly vs NIFTY 50)
0.44
Shares float
7.12 Cr
EPS · quarter ended Jun 2026
₹2.76
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹3,779.28 Cr | ₹4,557.58 Cr | ₹5,624.86 Cr | ₹6,087.46 Cr | ₹6,892.47 Cr | |
| EBITDA | — | ₹303.73 Cr | ₹311.75 Cr | ₹394.09 Cr | ₹535.72 Cr | ₹678.69 Cr |
| ₹64.00 Cr | ₹95.80 Cr | ₹49.76 Cr | ₹65.47 Cr | ₹150.32 Cr | ₹219.65 Cr | |
| Diluted EPS | — | ₹8.52 | ₹4.17 | ₹5.45 | ₹12.52 | ₹18.29 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,566.00 Cr | ₹2,594.00 Cr | ₹2,797.00 Cr | ₹3,005.00 Cr | ₹3,360.00 Cr | ₹3,933.00 Cr | |
| ₹590.21 Cr | ₹814.94 Cr | ₹899.92 Cr | ₹1,009.57 Cr | ₹1,119.80 Cr | ₹1,424.38 Cr | |
| Stockholders' equity | ₹730.45 Cr | ₹1,418.00 Cr | ₹1,491.00 Cr | ₹1,578.00 Cr | ₹1,741.00 Cr | ₹1,975.00 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3.00 Cr | ₹170.00 Cr | ₹90.00 Cr | ₹144.00 Cr | ₹540.00 Cr | ₹496.00 Cr | |
| Investing cash flow | — | ₹-703.13 Cr | ₹429.44 Cr | ₹-82.80 Cr | ₹-317.61 Cr | ₹-127.72 Cr |
| ₹-6.00 Cr | ₹440.00 Cr | ₹-170.00 Cr | ₹-198.00 Cr | ₹-228.00 Cr | ₹-256.00 Cr | |
| Capital expenditure | ₹-54.00 Cr | ₹-118.00 Cr | ₹-169.00 Cr | ₹-84.00 Cr | ₹-59.00 Cr | ₹-123.00 Cr |
| End cash position | — | ₹-121.23 Cr | ₹228.38 Cr | ₹91.21 Cr | ₹86.05 Cr | ₹198.41 Cr |
Change in working capital, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 21–Jun 22(4Q) | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.43% | 40.43% | 40.43% | 40.43% | 40.43% | 40.41% | 40.45% | 40.39% | 40.39% | 40.39% | 40.39% | 40.34% | 40.32% | 40.29% | 40.29% | 40.22% | 40.19% |
| Public | 59.22% | 59.23% | 59.28% | 59.38% | 59.42% | 59.47% | 59.45% | 59.51% | 59.54% | 59.55% | 59.57% | 59.62% | 59.63% | 59.66% | 59.66% | 59.74% | 59.77% |
| Employee trusts | 0.35% | 0.35% | 0.29% | 0.19% | 0.15% | 0.12% | 0.10% | 0.10% | 0.08% | 0.07% | 0.05% | 0.05% | 0.05% | 0.05% | 0.04% | 0.04% | 0.04% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Medplus Health Services Limited | ₹7,853.73 Cr | ₹659.65 | 37.3 | 3.98 | 11.1% | 0.72 | +12.3% | -21.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
3 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.